All In Biotech

Drug Trial Radar · NCT05684159

Study of NM8074 in Patients With aHUS With Evidence of Ongoing Thrombotic Microangiopathy

A Phase II, Open-Label Study of NM8074 in Patients With Atypical Hemolytic Uremic Syndrome (aHUS)

Last checked: Nov 19, 2026Latest source record: Apr 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

12

Planned (sponsor's estimate)

Start

Nov 2027

Primary completion

Apr 2030

Study completion Feb 2031

Sponsor

Lead sponsor
NovelMed TherapeuticsIndustry
Sponsor type
Industry
First posted
Jan 13, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase II, open-label study designed to determine if intravenously administered NM8074 results in remission from TMA in treatment-naïve aHUS patients.

Conditions

  • aHUS - Atypical Hemolytic Uremic Syndrome

Interventions

  • NM8074Drug

    NM8074 will be administered as an intravenous infusion. In Cohort 1, all subjects will be administered 20 mg/kg of NM8074 intravenously every two weeks for a total of 7 doses from Day 1 to Day 85 of the Treatment Period. Patients in Cohort 2 will receive weekly doses of 10 mg/kg for a total of 4 doses from Day 1 to Day 22 followed by biweekly doses at 20 mg/kg for a total of 5 doses from Day 29 to Day 85.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Normalization of platelet count (≥150 x 10^9/L)Time frame: Up to Study Day 120
  2. Normalization of LDH levels to below ULNTime frame: Up to Study Day 120
  3. Normalization of Schistocyte levels (<1%)Time frame: Up to Study Day 120
  4. Change from Baseline or Percent Change from Baseline in renal functionTime frame: Up to Study Day 120
  5. Change from Baseline or Percent Change from Baseline in HaptoglobinTime frame: Up to Study Day 120
  6. Change from Baseline or Percent Change from Baseline in HemoglobinTime frame: Up to Study Day 120
  7. Change from Baseline or Percent Change from Baseline in proteinuria/creatininuriaTime frame: Up to Study Day 120

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.